查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602172

治療性血漿交換市場：按技術、適應症、產品和最終用戶分類 - 全球預測 2025-2030 年

Therapeutic Plasma Exchange Market by Technology (Centrifugation, Membrane Separation), Indication (Hematologic Disorders, Metabolic Disorders, Neurological Disorders), Product, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年治療性血漿交換市場價值為7.9204億美元，預計到2024年將達到8.7853億美元，複合年成長率為9.81%，預計到2030年將達到15.2584億美元。

治療性血漿置換 (TPE) 是一種重要的醫療程序，涉及血漿的取出、治療和回輸，以治療各種健康狀況，包括自體免疫疾病、神經系統疾病和血液疾病。 TPE 的需求在於其清除血液中致病物質的能力，這對於對常規治療沒有反應的患者至關重要。 TPE已應用於治療Guillain-Barré二氏症候群、重症肌無力、血栓性血小板低下紫斑症、非典型溶血性尿毒症症候群等疾病，醫院和專科診所是主要終端用戶。由於自體免疫疾病的流行、醫療基礎設施的進步以及人口老化的加劇，TPE 市場正在不斷成長。技術進步，例如開發更有效率、更安全的單採設備，以及對 TPE 治療益處的認知不斷提高，是關鍵的成長動力。然而，市場面臨手術成本高、報銷政策有限以及對熟練醫療專業人員的需求等挑戰。此外，發展中地區熟練技術人員的稀缺和取得機會有限也阻礙了成長。儘管存在這些挑戰，但仍存在將應用擴展到新的自體免疫疾病以及在具有成本效益且易於使用的單採設備方面進行創新的機會。對研發以及策略聯盟和夥伴關係的投資有可能加速成長並擴大應用範圍。公司可以利用資料分析來最佳化程序並改善患者的治療效果。此外，遠端醫療可以支援遠端監控和治療後護理，付加服務提供的價值。然而，有關醫療設備認證的法規和血漿採購的道德影響凸顯了需要仔細關注的領域。為了保持競爭力，公司應專注於個人化醫療方法並整合先進技術，提供適合患者獨特需求的治療性血漿置換解決方案。

主要市場統計
基準年[2023] 79204萬美元
預測年份 [2024] 87853萬美元
預測年份 [2030] 15.2584億美元
複合年成長率（%） 9.81%

市場動態：快速發展的治療性血漿交易市場的關鍵市場洞察

供需的動態交互作用正在改變治療性血漿置換市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於自體免疫疾病和心臟病的盛行率不斷增加，需要進行治療性血漿置換
    • 單採技術的進步
  • 市場限制因素
    • 與設備和治療性血漿置換程序相關的成本
  • 市場機會
    • 神經肌肉疾病治療性血漿置換技術與免疫調節作用的進展
    • 兒科加護治療中治療性血漿置換 (TPE) 的需求迅速成長
  • 市場挑戰
    • TPE 中與血漿分離術相關的併發症

波特五力：駕馭治療性血漿交換市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解治療性血漿交換市場的外部影響

外部宏觀環境因素在塑造治療性血漿交換市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解治療性血漿置換市場的競爭格局

治療性血漿交換市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣治療性血漿置換市場供應商的績效評估

FPNV 定位矩陣是評估治療性血漿置換市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於自體免疫疾病和心臟病盛行率上升，需要進行治療性血漿置換
      • 單採技術的技術進步
    • 抑制因素
      • 與設備和治療性血漿置換程序相關的成本
    • 機會
      • 神經肌肉疾病治療血漿置換技術和免疫調節作用的進展
      • 兒科加護治療中治療性血漿置換 (TPE) 的需求快速成長
    • 任務
      • 與 TPE 成分分析程序相關的併發症
  • 市場區隔分析
    • 技術：膜分離是首選，但治療性血漿置換
    • 適應症：廣泛使用治療性血漿置換治療危及生命的血液疾病
    • 產品：耗材的技術進步必須與血漿置換設備和系統相容。
    • 最終用戶：採血中心和血液成分供應商正在獲得更大的用戶群和大規模手術治療的支持。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 治療性血漿交換市場：依技術分類

  • 離心
  • 膜分離

第7章 治療性血漿交易市場（依適應症分類）

  • 血液疾病
    • 非典型溶血性尿毒症綜合症
    • 高黏滯症候群
    • 嚴重/有症狀的冷球蛋白血症
    • 血栓性血小板低下紫斑症
  • 代謝紊亂
  • 神經系統疾病
    • 慢性脫髓鞘多發性神經炎
    • 格林-巴利綜合症
    • 多發性硬化症
    • 重症肌無力
    • PANDAS
  • 腎臟疾病
    • 抗體介導的腎臟移植排斥反應
    • 古德帕斯特症候群
    • 韋格納肉芽腫

第8章 治療性血漿交換市場：依產品

  • 消耗品
  • 裝置

第9章 治療性血漿交換市場：依最終用戶分類

  • 採血中心及血液成分供應商
  • 醫院及輸血中心

第10章 美洲治療性血漿交易市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區治療性血漿交易市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的治療性血漿交易市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Savage 醫師將於 2024 年推出血漿置換減重法
    • HealthyLongevity.clinic 最近與 Dobri Kiprov 博士合作
    • MaxWell Clinic 提供治療性血漿置換 (TPE) 作為失智症、阿茲海默症、記憶力衰退和自體免疫疾病的治療選擇。

公司名單

  • Asahi Kasei Medical Co., Ltd.
  • Haemonetics Corporation
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Medica SPA
  • Elastrin Therapeutics, Inc.
  • B. Braun Melsungen AG
  • Pall Corporation
  • Medicap Clinic GmbH
  • Infomed SA
  • Terumo BCT, Inc.
  • Qingdao Haier Biomedical Co., Ltd
  • Mallinckrodt PLC
  • Fresenius Medical Care AG & Co. KGaA
  • Kaneka Corporation
  • MEISE Medizintechnik GmbH
  • Nikkiso Co., Ltd.
  • Grifols, SA
  • Sb-Kawasumi Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Cerus Corporation
  • Plasma Technologies, LLC
  • Miltenyi Biotec
  • Bio Products Laboratory Ltd.
  • Baxter International Inc.
Product Code: MRR-BC0B37A58A34

The Therapeutic Plasma Exchange Market was valued at USD 792.04 million in 2023, expected to reach USD 878.53 million in 2024, and is projected to grow at a CAGR of 9.81%, to USD 1,525.84 million by 2030.

Therapeutic Plasma Exchange (TPE) is a vital medical procedure involving the removal, treatment, and reinfusion of plasma to manage various health conditions such as autoimmune diseases, neurological disorders, and hematological disorders. Its necessity arises from the procedure's ability to remove pathogenic substances from the blood, which is crucial for patients unresponsive to conventional treatments. TPE finds applications in treating diseases like Guillain-Barre Syndrome, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, and Atypical Hemolytic Uremic Syndrome, with hospitals and specialty clinics being primary end-users. The market for TPE is growing, driven by increasing incidences of autoimmune diseases, advancements in healthcare infrastructure, and a rising aging population. Technological advancements like the development of more efficient and safer apheresis devices and increasing awareness of TPE's therapeutic benefits are key growth drivers. However, the market faces challenges such as high procedural costs, limited reimbursement policies, and the need for highly skilled healthcare professionals. Additionally, the scarcity of skilled technicians and limited accessibility in developing regions hinder growth. Despite these challenges, opportunities lie in expanding applications for emerging autoimmune conditions and innovating cost-effective and user-friendly apheresis devices. Investment in research and development, along with strategic collaborations and partnerships, could accelerate growth and widen the application scope. Companies can leverage data analytics to optimize procedures and enhance patient outcomes. Furthermore, telemedicine can support remote monitoring and post-treatment care, adding value to service delivery. However, regulations concerning medical device approval and the ethical implications of plasma procurement highlight areas requiring careful navigation. To stay competitive, companies should focus on personalized medicine approaches, integrating advanced technology to offer tailored therapeutic plasma exchange solutions that align with patient-specific needs.

KEY MARKET STATISTICS
Base Year [2023] USD 792.04 million
Estimated Year [2024] USD 878.53 million
Forecast Year [2030] USD 1,525.84 million
CAGR (%) 9.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Plasma Exchange Market

The Therapeutic Plasma Exchange Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
    • Technical Advancement in Apheresis Technologies
  • Market Restraints
    • Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
  • Market Opportunities
    • Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
    • Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
  • Market Challenges
    • Complications Associated with the Apheresis Procedure in TPE

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Plasma Exchange Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Plasma Exchange Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Plasma Exchange Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Plasma Exchange Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Plasma Exchange Market

A detailed market share analysis in the Therapeutic Plasma Exchange Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Plasma Exchange Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Plasma Exchange Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Plasma Exchange Market, highlighting leading vendors and their innovative profiles. These include Asahi Kasei Medical Co., Ltd., Haemonetics Corporation, CSL Behring, Kedrion Biopharma Inc., Medica S.P.A., Elastrin Therapeutics, Inc., B. Braun Melsungen AG, Pall Corporation, Medicap Clinic GmbH, Infomed SA, Terumo BCT, Inc., Qingdao Haier Biomedical Co., Ltd, Mallinckrodt PLC, Fresenius Medical Care AG & Co. KGaA, Kaneka Corporation, MEISE Medizintechnik GmbH, Nikkiso Co., Ltd., Grifols, S.A., Sb-Kawasumi Laboratories, Inc., Charles River Laboratories International, Inc., Cerus Corporation, Plasma Technologies, LLC, Miltenyi Biotec, Bio Products Laboratory Ltd., and Baxter International Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Plasma Exchange Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Centrifugation and Membrane Separation.
  • Based on Indication, market is studied across Hematologic Disorders, Metabolic Disorders, Neurological Disorders, and Renal Disorders. The Hematologic Disorders is further studied across Atypical Hemolytic Uremic Syndrome, Hyperviscosity Syndrome, Severe/Symptomatic Cryoglobulinemia, and Thrombotic Thrombocytopenic Purpura. The Neurological Disorders is further studied across Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, and PANDAS. The Renal Disorders is further studied across Antibody-mediated Renal Transplant Rejection, Goodpasture Syndrome, and Wegener's Granulomatosis.
  • Based on Product, market is studied across Consumables and Devices.
  • Based on End-user, market is studied across Blood Collection Centers & Blood Component Providers and Hospitals & Transfusion Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
      • 5.1.1.2. Technical Advancement in Apheresis Technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
      • 5.1.3.2. Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
    • 5.1.4. Challenges
      • 5.1.4.1. Complications Associated with the Apheresis Procedure in TPE
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Membrane separation are preferred selection while therapeutic plasma exchange
    • 5.2.2. Indication: Extensive usage of therapeutic plasma exchange for life threatening hematologic disorders
    • 5.2.3. Product: Technological advancement in consumables needs should to be compatible with their plasma exchange devices and systems
    • 5.2.4. End-user: Blood collection centers & blood component providers are commanding larger user base and support for large scale operative treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Therapeutic Plasma Exchange Market, by Technology

  • 6.1. Introduction
  • 6.2. Centrifugation
  • 6.3. Membrane Separation

7. Therapeutic Plasma Exchange Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematologic Disorders
    • 7.2.1. Atypical Hemolytic Uremic Syndrome
    • 7.2.2. Hyperviscosity Syndrome
    • 7.2.3. Severe/Symptomatic Cryoglobulinemia
    • 7.2.4. Thrombotic Thrombocytopenic Purpura
  • 7.3. Metabolic Disorders
  • 7.4. Neurological Disorders
    • 7.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 7.4.2. Guillain-Barre Syndrome
    • 7.4.3. Multiple Sclerosis
    • 7.4.4. Myasthenia Gravis
    • 7.4.5. PANDAS
  • 7.5. Renal Disorders
    • 7.5.1. Antibody-mediated Renal Transplant Rejection
    • 7.5.2. Goodpasture Syndrome
    • 7.5.3. Wegener's Granulomatosis

8. Therapeutic Plasma Exchange Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Devices

9. Therapeutic Plasma Exchange Market, by End-user

  • 9.1. Introduction
  • 9.2. Blood Collection Centers & Blood Component Providers
  • 9.3. Hospitals & Transfusion Centers

10. Americas Therapeutic Plasma Exchange Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Plasma Exchange Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Plasma Exchange Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Dr. Savage Introduces Plasma Exchange for 2024 Weight Loss
    • 13.3.2. HealthyLongevity.clinic recently partnered with Dr. Dobri Kiprov
    • 13.3.3. MaxWell Clinic offers Therapeutic Plasma Exchange (TPE) as a Treatment Option for Dementia, Alzheimer's, Memory Los, and Autoimmune Disease

Companies Mentioned

  • 1. Asahi Kasei Medical Co., Ltd.
  • 2. Haemonetics Corporation
  • 3. CSL Behring
  • 4. Kedrion Biopharma Inc.
  • 5. Medica S.P.A.
  • 6. Elastrin Therapeutics, Inc.
  • 7. B. Braun Melsungen AG
  • 8. Pall Corporation
  • 9. Medicap Clinic GmbH
  • 10. Infomed SA
  • 11. Terumo BCT, Inc.
  • 12. Qingdao Haier Biomedical Co., Ltd
  • 13. Mallinckrodt PLC
  • 14. Fresenius Medical Care AG & Co. KGaA
  • 15. Kaneka Corporation
  • 16. MEISE Medizintechnik GmbH
  • 17. Nikkiso Co., Ltd.
  • 18. Grifols, S.A.
  • 19. Sb-Kawasumi Laboratories, Inc.
  • 20. Charles River Laboratories International, Inc.
  • 21. Cerus Corporation
  • 22. Plasma Technologies, LLC
  • 23. Miltenyi Biotec
  • 24. Bio Products Laboratory Ltd.
  • 25. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC PLASMA EXCHANGE MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC PLASMA EXCHANGE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC PLASMA EXCHANGE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC PLASMA EXCHANGE MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MEMBRANE SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HYPERVISCOSITY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY SEVERE/SYMPTOMATIC CRYOGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY THROMBOTIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PANDAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ANTIBODY-MEDIATED RENAL TRANSPLANT REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GOODPASTURE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY WEGENER'S GRANULOMATOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HOSPITALS & TRANSFUSION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)